In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Dolezal has given his Buy rating due to a combination of factors tied to iBio’s differentiated obesity pipeline and improving financial position. He points to IBIO-610, an anti–activin E antibody for obesity, as a key value driver, noting that recent competitor data targeting the same pathway substantially de-risks the mechanism and suggests meaningful potential for visceral fat and weight reduction.
He also highlights that IBIO-610 appears unique as the only antibody-based activin E program in development, offering potential advantages over siRNA approaches, including deeper target suppression, co-formulation flexibility with GLP‑1 agents, and scalable manufacturing. In addition, he underscores the recent $26 million private placement, which extends the company’s cash runway and enables acceleration of IBIO-600 into Phase 1a in the first half of 2026, collectively reinforcing the investment case for the shares.